A groundbreaking experimental medication is providing renewed optimism for individuals battling pancreatic cancer, known for being one of the most lethal and challenging types of cancer to treat.
Findings from a substantial global study, unveiled at the annual meeting of the American Society of Clinical Oncology (ASCO), indicated that daraxonrasib, a daily oral medication, nearly doubled the survival duration for patients with advanced pancreatic cancer whose condition had deteriorated despite prior treatments.
This innovative drug targets the KRAS gene, a mutation associated with tumor growth that is prevalent in most pancreatic cancer cases. Researchers have been striving for decades to find effective ways to inhibit this mutation. The study results have sparked enthusiasm among oncologists, as advancements in the treatment of pancreatic cancer have been historically minimal.
Professor Anant Ramaswamy, an expert in gastrointestinal cancers and geriatric oncology at the Tata Memorial Centre in Mumbai, noted, “For many years, the average survival time for patients with advanced pancreatic cancer has remained around one year. It was six months during the late 1990s, and only increased to about 9-12 months over the past thirty years. Despite extensive research efforts, improvements in survival rates have been marginal over the last two decades.”
He further stated, “In this context, the introduction of an oral medication that can improve or even double survival rates in patients who have undergone prior treatment is incredibly promising. This marks just the beginning for this new category of drugs, and both patients and oncologists can look forward to further advancements in the future,” as reported by The Indian Express.
Why has pancreatic cancer proven to be particularly resistant to treatment compared to other forms of cancer? Several factors contribute to this challenge. Firstly, a significant majority of patients (70-90%) are diagnosed at an advanced stage, which limits treatment options. Secondly, while many other cancer types have benefited from targeted therapies and immunotherapy leading to improved outcomes, these strategies have yet to show substantial benefits for pancreatic cancer. Additionally, the tumor’s surrounding tissue, known as the stroma, has also shown resistance to current treatment methods.
The KRAS gene plays a crucial role in pancreatic cancer. Daraxonrasib works by effectively “locking onto” the mutated KRAS gene. To explain its mechanism simply, RAS is a protein that is found in nearly all cell types in the human body, encoded by the RAS gene. Mutations in the RAS gene family, particularly KRAS, occur in about 20% of all cancers, with roughly 80% of pancreatic cancers displaying alterations in KRAS, making it a significant focus for research.
When the KRAS gene mutates, it becomes persistently active, leading to the disruption of normal cellular functions and promoting cancer development. Daraxonrasib acts to inhibit this activity within the cell, suppressing pathways that contribute to cancer cell proliferation. It is the first drug in its class to demonstrate such promising results, with several similar drugs currently in development expected to be available in the coming years.
What distinguishes daraxonrasib from existing therapies? This drug is the first to effectively inhibit RAS activity across various RAS subtypes, regardless of whether they are mutated, marking a significant achievement in the realm of precision oncology.
While daraxonrasib is an oral medication, it has been associated with a notable incidence of side effects comparable to those seen with chemotherapy. Common side effects reported by patients included skin rashes, diarrhea, mouth ulcers, nausea, fatigue, and decreased hemoglobin levels. Approximately one-third of patients experienced a need for dosage adjustments. As this drug is new, oncologists globally will gradually adapt its use to manage side effects more effectively.
Currently, patients with pancreatic cancer who have previously received chemotherapy and are experiencing disease progression are eligible for daraxonrasib treatment. Ongoing clinical trials are investigating the drug’s application in treatment-naïve patients, with expectations that it may be used earlier in the treatment process for pancreatic and other types of cancer in the near future.
Could this drug have potential uses beyond pancreatic cancer? Daraxonrasib, along with similar RAS inhibitors, is being studied for effectiveness in various cancers, as RAS mutations occur in approximately 20% of all cancer cases. It is currently under evaluation for lung and colon cancers, which are more prevalent and also exhibit a high incidence of RAS mutations.
As for accessibility, daraxonrasib is not yet available in India, but due to its promising potential, it is anticipated that this class of drugs will soon be introduced in the country. There are reports of long waitlists for access to clinical trials investigating RAS inhibitors, indicating a strong interest in these therapies.
This breakthrough underscores the evolving landscape of precision medicine in cancer treatment, highlighting the potential for tailored therapies to significantly improve outcomes for patients with challenging cancers like pancreatic cancer.
